Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Anthi Bouchla, Theodoros Loupis, Georgia Delikonstantinos, Frieda Kontsioti, Vassiliki Mpakou, Maria Dellatola, Maria Pagoni, Konstantinos Theodorakopoulos, Sotirios Papageorgiou, Argiris Symeonidis, Vassiliki Pappa

Blood (2022) 140 (Supplement 1): 6250–6251.

https://doi.org/10.1182/blood-2022-158980

Published: 2022

Journal Articles

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Christina-Nefeli Kontandreopoulou, Stavroula Syriopoulou, Panagiotis T Diamantopoulos, Nefeli Giannakopoulou, Dimitra Vlachopoulou, Panagiota Katsiampoura, Christos Stafylidis, Maria Dimou, Athanasios Galanopoulos, Sotirios Papageorgiou, Eleftheria Hatzimichael, Vassiliki Pappa, Kotsianidis Ioannis, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou

Blood (2022) 140 (Supplement 1): 6958–6959.

https://doi.org/10.1182/blood-2022-165870

Published: 2022

Journal Articles

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Blood (2021) 138 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2021-149630

Published: 2021

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136940

Published: 2020

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Panagiotis T Diamantopoulos, MD PhD, Vassiliki Pappa, MD, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, Alexandra Kourakli, MD PhD, Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Elena E. Solomou, MD, Anastasia Pouli, MD PhD, Panagiotis Panagiotidis, MD PhD, Maria Dimou, MD PhD, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, MD MSc, Anna Vardi, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Georgia Kaiafa, MD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, PhD, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, MD PhD, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5427.

https://doi.org/10.1182/blood-2019-127417

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Frieda Kontsioti, PhD, Zoi Tsakiraki, MD, Sotirios Papageorgiou, MD PhD, Efthimia Mpazani, MD, Irene Glezou, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Athanasios Galanopoulos, MD PhD, Argiris Symeonidis, MD PhD, Nora-Athina Viniou, MD PhD, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, MD PhD, Periklis Foukas, MD PhD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5403.

https://doi.org/10.1182/blood-2019-122424

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD

Blood (2019) 134 (Supplement_1): 5417.

https://doi.org/10.1182/blood-2019-131003

Published: 2019

Journal Articles

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, PhD, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, MD PhD, Evangelia Nakou, Anastasia Hadzidimitriou, PhD, George Kassiotis, Elli Papaemmanuil, PhD, Ioannis Mitroulis, Ioannis Kotsianidis

Blood (2019) 134 (Supplement_1): 2988.

https://doi.org/10.1182/blood-2019-126504

Published: 2019

Journal Articles

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Christina-Nefeli Kontandreopoulou, BSc, Panagiotis T Diamantopoulos, MD PhD, Argiris Symeonidis, MD PhD, Ioannis Kotsianidis, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Andreas Giannopoulos, BSc, MSc, Katerina Zoi, PhD, Maria Dimou, MD PhD, Elena E. Solomou, MD, Panayiotis Panayiotidis, MD, Georgios Kyriakakis, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Chatzidavid, Nora-Athina Viniou, MD PhD

Blood (2019) 134 (Supplement_1): 1721.

https://doi.org/10.1182/blood-2019-126426

Published: 2019

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Vassiliki Mpakou, PhD, Aris Spathis, PhD, Anthi Bouhla, MD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Irene Glezou, MD, Sotirios Papageorgiou, MD PhD, Efthimia Bazani, MD, Diamantina Vasilatou, MD, Nora Viniou, MD, Athanasios Galanopoulos, MD PhD, Kalliopi Zafeiropoulou, Kotsianidis Ioannis, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 3825.

https://doi.org/10.1182/blood.V130.Suppl_1.3825.3825

Published: 2017

Journal Articles

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

Ioannis Kotsianidis, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, Alexandra Kourakli, Theodoros Vassilakopoulos, MDPhD, Menelaos Konstantinos Papoutselis, Zoi Topouzoglou, Panagiotis Theodorou Diamantopoulos, MD PhD, Dimitrios Τsokanas, Argiris Symeonidis, MD PhD

Blood (2017) 130 (Supplement 1): 4251.

https://doi.org/10.1182/blood.V130.Suppl_1.4251.4251

Published: 2017

Journal Articles

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

Sotirios Papageorgiou, MD PhD, Christos K. Kontos, PhD, Thomas Tsiambalis, Athina Vyniou, Argiris Symeonidis, MD PhD, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, PhD, Vassiliki Pappa, MD

Blood (2017) 130 (Supplement 1): 4252.

https://doi.org/10.1182/blood.V130.Suppl_1.4252.4252

Published: 2017

Journal Articles

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Panagiotis Theodorou Diamantopoulos, MD PhD, Ioannis Kotsianidis, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Dimitrios Gogos, Paraskevi Roussou, Helen A. Papadaki, MD PhD, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sossana Delibasi, Menelaos Konstantinos Papoutselis, Alexandra Kourakli, MD, Dimitrios Tsokanas, Niki Rougala, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2974.

https://doi.org/10.1182/blood.V130.Suppl_1.2974.2974

Published: 2017

Journal Articles

Natural Killer Cell Cytotoxicity Is a Predictor of Outcome for Patients with High Risk Myelodysplastic Syndrome and Oligoblastic Acute Myeloid Leukemia Treated with Azacytidine

Panagiotis Tsirigotis, Renata Grigoriou, Violetta Kapsimalli, Kleopatra Dagla, Evi Konsta, Konstantinos Gkirkas, Maria Stamouli, Aggeliki Karagiannidi, George Vassilopoulos, MD PhD, Konstantinos Gkodopoulos, MD, Vassiliki Pappa, MD, Maria Tsirogianni

Blood (2017) 130 (Supplement 1): 2976.

https://doi.org/10.1182/blood.V130.Suppl_1.2976.2976

Published: 2017

NARROW

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Molecular Mechanisms of Primary Resistance to Azacitidine in MDS/AML Patients - Data of the Hellenic MDS Study Group

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Bone Marrow Ribonucleotide Reductase mRNA Levels and Methylation Status As a Prognostic Factor in Patients with Myelodysplastic Syndrome Treated with 5-Azacytidine

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

The Association of Hif-1α Expression with Primary Resistance to Azacytidine in Patients with High Risk MDS — Preliminary Data of the Hellenic MDS Study Group

Azacytidine Failure Revisited: An Appraisal Based on Real Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)

The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Natural Killer Cell Cytotoxicity Is a Predictor of Outcome for Patients with High Risk Myelodysplastic Syndrome and Oligoblastic Acute Myeloid Leukemia Treated with Azacytidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only